中国医药
中國醫藥
중국의약
CHINA MEDICINE
2012年
8期
998-999
,共2页
帕洛诺司琼%昂丹司琼%化疗%恶心%呕吐
帕洛諾司瓊%昂丹司瓊%化療%噁心%嘔吐
파락낙사경%앙단사경%화료%악심%구토
Palonosetron%Ondansetron%Chemotherapy%Nausea%Vomiting
目的 观察和评价帕洛诺司琼联合地塞米松预防中度致吐化疗方案所致恶心、呕吐(CINV)的临床疗效和不良反应.方法 60例患者采用中度致吐方案化疗,按随机抽样法随机分为帕洛诺司琼组和昂丹司琼组,各30例.帕洛诺司琼组给予盐酸帕洛诺司琼0.25 mg,第1天化疗前30 min静脉注射.昂丹司琼组给予盐酸昂丹司琼8 mg,化疗前30 min缓慢静脉滴注,连用3d.2组均联合地塞米松5 mg静脉注射.观察5d内恶心、呕吐等不良反应发生情况并作比较.结果 帕洛诺司琼组与昂丹司琼组急性CINV完全缓解率分别为80.0％ (24/30)和76.7％(23/30),有效控制率分别为93.3％(28/30)和86.7％(26/30),差异无统计学意义(P＞0.05)；延迟性CINV完全缓解率分别为76.7％ (23/30)和63.3％(19/30),差异无统计学意义(P＞0.05),有效控制率分别为93.4％(28/30)和73.3％(22/30),差异有统计学意义(P＜0.05).2组不良反应发生率均较低,组间差异无统计学意义(P＞0.05).结论 帕洛诺司琼预防中度致吐化疗方案所致急性CINV 疗效与昂丹司琼相当,对延迟性CINV 的疗效优于昂丹司琼,不良反应程度较轻、安全性好.
目的 觀察和評價帕洛諾司瓊聯閤地塞米鬆預防中度緻吐化療方案所緻噁心、嘔吐(CINV)的臨床療效和不良反應.方法 60例患者採用中度緻吐方案化療,按隨機抽樣法隨機分為帕洛諾司瓊組和昂丹司瓊組,各30例.帕洛諾司瓊組給予鹽痠帕洛諾司瓊0.25 mg,第1天化療前30 min靜脈註射.昂丹司瓊組給予鹽痠昂丹司瓊8 mg,化療前30 min緩慢靜脈滴註,連用3d.2組均聯閤地塞米鬆5 mg靜脈註射.觀察5d內噁心、嘔吐等不良反應髮生情況併作比較.結果 帕洛諾司瓊組與昂丹司瓊組急性CINV完全緩解率分彆為80.0％ (24/30)和76.7％(23/30),有效控製率分彆為93.3％(28/30)和86.7％(26/30),差異無統計學意義(P＞0.05)；延遲性CINV完全緩解率分彆為76.7％ (23/30)和63.3％(19/30),差異無統計學意義(P＞0.05),有效控製率分彆為93.4％(28/30)和73.3％(22/30),差異有統計學意義(P＜0.05).2組不良反應髮生率均較低,組間差異無統計學意義(P＞0.05).結論 帕洛諾司瓊預防中度緻吐化療方案所緻急性CINV 療效與昂丹司瓊相噹,對延遲性CINV 的療效優于昂丹司瓊,不良反應程度較輕、安全性好.
목적 관찰화평개파락낙사경연합지새미송예방중도치토화료방안소치악심、구토(CINV)적림상료효화불량반응.방법 60례환자채용중도치토방안화료,안수궤추양법수궤분위파락낙사경조화앙단사경조,각30례.파락낙사경조급여염산파락낙사경0.25 mg,제1천화료전30 min정맥주사.앙단사경조급여염산앙단사경8 mg,화료전30 min완만정맥적주,련용3d.2조균연합지새미송5 mg정맥주사.관찰5d내악심、구토등불량반응발생정황병작비교.결과 파락낙사경조여앙단사경조급성CINV완전완해솔분별위80.0％ (24/30)화76.7％(23/30),유효공제솔분별위93.3％(28/30)화86.7％(26/30),차이무통계학의의(P＞0.05)；연지성CINV완전완해솔분별위76.7％ (23/30)화63.3％(19/30),차이무통계학의의(P＞0.05),유효공제솔분별위93.4％(28/30)화73.3％(22/30),차이유통계학의의(P＜0.05).2조불량반응발생솔균교저,조간차이무통계학의의(P＞0.05).결론 파락낙사경예방중도치토화료방안소치급성CINV 료효여앙단사경상당,대연지성CINV 적료효우우앙단사경,불량반응정도교경、안전성호.
Objective To observe and evaluate clinical effect of palonosetron hydrochloride and ondansetron hydrochloride that are used to prevent the chemotherapy-induced nausea and vomiting(CINV)caused by moderately emetogenic chemotherapy.Methods Sixty cases of cancer chemotherapy were divided into 2 groups:palonosetron group(n =30)and ondansetron group(n =30).Palonosetron group were given palonosetron hydrochloride 0.25 mg,intravenous infusion 30 min before chemotherapy on the first day.Ondansetron group was given ondansetron hydrochloride 8 mg,slow intravenous infusion 30 min before chemotherapy for three days.Dexamethasone 5 mg intravenous injection was used in the two groups.The situation of nausea and vomiting and adverse reactions were observed and recorded respectively in a period of 5 days after chemotherapy.Results In controlling acute CINV,the complete remission rate in palonosetron group was 80.0％ (24/30)and it was 76.7％ (23/30)in ondansetron group (P ＞ 0.05).The effective rate in palonosetron group was 93.3％ (28/30)and it was 86.7％ in ondansetron group (26/30)(P ＞ 0.05).In controlling delayed CINV,palonosetron hydrochloride was superior to ondansetron hydrochloride.The complete remission rate in palonosetron group was 76.7％ (23/30)and it was 63.3％ (19/30)in ondansetron group (P＞0.05).The effective rate was 93.4％ (28/30)in palonosetron group and 73.3％ (22/ 30)in ondansetron group(P ＜ 0.05).There was no significant difference in the adverse reactions between the two groups (P ＞ 0.05).Conclusions Palonosetron hydrochloride is superior to ondansetron hydrochloride in controlling delayed CINV caused by moderately emetogenic chemotherapy.There is no significant difference in controlling delayed CINV.It has few adverse reactions and should be used widely in clinic.
